BioSpace News Archive

Soft tissue regeneration company Aroa Biosurgery Limited has this week launched Myriad Morcells™, a morcellized format of Myriad Matrix™ that easily conforms to optimize contact with irregular wound beds.

Initial pharmacokinetic (PK), safety, and preliminary efficacy data from Phase 1 dose-escalation portion of MasterKey-01 clinical trial to be presented

Marrone Bio Innovations, Inc., an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, released an update letter to shareholders from Chief Executive Officer Kevin Helash.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, May 4, 2021 at 5pm ET to discuss its financial results and corporate update for the first quarter ended March 31, 2021.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, May 5, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2021 financial results and to provide a corporate update.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today announced it has entered into a definitive agreement with institutional investors in a private placement of 3,669,724 shares of common stock and warrants to purchase 1,834,862 shares of common stock at a combined purchase price of $2.18 per share for gross proceeds of approximately $8,000,000 before deducting fees and other estimated offering expenses.

Alercell, announced today that it will begin distributing the Clip COVID Rapid Antigen Test, a revolutionary antigen analyzer along with its antigen COVID-19 test collection kits, across the U.S through its network and partnerships.

The Allen Institute and BioMarin Pharmaceutical Inc. announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic diseases of the central nervous system

ReAlta Life Sciences, Inc., today announced that the Company has successfully closed a Series A3 financing of $20 million.

Health Passport Subsidiary Medcheks has Launched Next-Generation, Scalable Reopening Tools to Enable Expedited Post-COVID-19 Reopening to Align with Rapidly Evolving Global Mandates